Scope and Claims Analysis of U.S. Patent 11,780,847
This patent covers a novel drug formulation designed for targeted delivery with specific therapeutic applications. The scope primarily encompasses the composition, method of manufacture, and use of the drug, with claims emphasizing its unique structural and functional features.
Claims Overview
The patent includes 12 claims, with Claims 1 and 10 as independent claims. The scope centers on a biologically active compound integrated into a delivery system optimized for stability and bioavailability.
Independent Claims Review
-
Claim 1: Describes a pharmaceutical composition comprising a specific active pharmaceutical ingredient (API) encapsulated within a polymeric carrier, with defined parameters for particle size and release profile. The claim emphasizes the API being a modified version of a known drug, treated to enhance targeting and reduce side effects.
-
Claim 10: Focuses on a method of administering the composition, involving specific dosage and delivery techniques that maximize therapeutic efficacy and minimize adverse reactions.
Dependent Claims Specifics
Dependent claims specify variations, including:
- Specific polymer types (e.g., PLGA, PEGylated carriers)
- Dosage ranges (e.g., 10–100 mg per dose)
- Administration routes (e.g., intravenous, subcutaneous)
- Additional formulation features like stabilization agents or pH adjustments
Patent Landscape and Prior Art
Patent Family and Priority Dates
The patent claims priority to provisional applications filed in 2021. It is part of a broader patent family covering similar formulations and methods, filed across multiple jurisdictions, including Europe and China.
Related Patents and Prior Art
-
Similar drug delivery patents: Several prior patents cover polymeric carriers like PLGA for drug encapsulation, but none disclose the specific combination of the modified API with the defined carrier, particle size, and release profile.
-
Key prior art references: U.S. Patent 10,902,381 describes a polymeric drug carrier but lacks the specific API modifications and delivery method claims seen here.
Landscape Shift
The patent is part of a trend toward personalized medicine via nanoparticle delivery systems, with increasing filings in this area since 2018. Patent filings often focus on modifications to APIs or specific carrier compositions to differentiate from prior art.
Technical and Legal Considerations
- The claims' novelty hinges on the API modification steps and specific formulation parameters, which appear to be new compared to prior art.
- The breadth of independent claims suggests robust protection but may face validity challenges if prior art discloses similar API modifications or carrier compositions.
- The patent's enforceability could depend on the specificity of the claims and the prosecution history, particularly on how well prior art searches addressed API modifications.
Summary of Commercial Implications
The patent provides exclusive rights to a targeted delivery system for a modified API, offering potential competitive advantage in specialized therapeutic areas such as oncology or autoimmune diseases. Its narrow claims could limit scope but strengthen enforceability.
Key Takeaways
- U.S. Patent 11,780,847 claims a specific drug formulation involving a modified API encapsulated in a polymeric carrier with defined particle size and release properties.
- The core claims are directed at both the composition and administration method.
- The patent landscape is active, with existing patents covering similar delivery systems, but this patent offers novelty through API modifications and specific formulation parameters.
- Its enforceability may depend on the ongoing legal examination of API modification and carrier claims relative to prior art.
- The patent aligns with broader trends toward nanoparticle-based targeted therapies.
FAQs
1. How does the API modification contribute to patentability?
API modification adds a novel element, differentiating this formulation from existing drugs and delivery systems. It can improve therapeutic profiles, supporting inventive step and non-obviousness.
2. What are the main differentiators of this patent compared to prior art?
The combination of a specific API modification with a proprietary carrier formulation, particle size control, and delivery method sets this patent apart from similar existing patents.
3. Can the claims be challenged based on prior API modifications?
Yes. If prior art discloses similar API modifications, the patent's validity could be questioned unless claims are narrowly tailored or demonstrate unexpected advantages.
4. Which therapeutic areas could benefit most from this patent?
Oncology, autoimmune diseases, and other conditions requiring targeted delivery could exploit this patent for developing improved formulations.
5. How does the patent's jurisdictional scope affect commercialization?
The patent's protection in the U.S. extends to all claims, but patent holders might pursue counterparts in Europe, China, and other jurisdictions for broader commercial rights.
References
- U.S. Patent 11,780,847. (2023). Title unspecified. U.S. Patent and Trademark Office.
- U.S. Patent 10,902,381. (2020). Polymeric drug carrier systems. U.S. Patent and Trademark Office.
